{"entity": "researcher", "timestamp": "2026-09-29T15:22:22.310Z", "family": "\u00d6sterborg", "given": "Anders", "initials": "A", "orcid": "0000-0001-6489-4865", "affiliations": ["Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.", "Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/20620d6f76924b4a82239eb57061bd67.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/20620d6f76924b4a82239eb57061bd67"}}, "publications": [{"entity": "publication", "iuid": "7de71475014744daa18700e2e5c2688d", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7de71475014744daa18700e2e5c2688d.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7de71475014744daa18700e2e5c2688d"}}, "title": "Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.", "authors": [{"family": "Chen", "given": "Puran", "initials": "P"}, {"family": "Bergman", "given": "Peter", "initials": "P", "orcid": "0000-0003-3306-3713", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9804a8732d334e96bfec5915e198bc02.json"}}, {"family": "Blennow", "given": "Ola", "initials": "O"}, {"family": "Hansson", "given": "Lotta", "initials": "L", "orcid": "0000-0001-6614-5737", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ad4bcbe463b0417e92258dbf5cb14886.json"}}, {"family": "Mielke", "given": "Stephan", "initials": "S", "orcid": "0000-0002-8325-9215", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/e252f7353163408cad14e163349e0fa4.json"}}, {"family": "Nowak", "given": "Piotr", "initials": "P", "orcid": "0000-0003-2747-0734", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1b916fcba1024b208ed996cf957f499c.json"}}, {"family": "Gao", "given": "Yu", "initials": "Y"}, {"family": "S\u00f6derdahl", "given": "Gunnar", "initials": "G"}, {"family": "\u00d6sterborg", "given": "Anders", "initials": "A", "orcid": "0000-0001-6489-4865", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/20620d6f76924b4a82239eb57061bd67.json"}}, {"family": "Smith", "given": "C I Edvard", "initials": "CIE", "orcid": "0000-0003-1907-3392", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/357ca5f9684948fb89f138da8c2c9aa2.json"}}, {"family": "Vesterbacka", "given": "Jan", "initials": "J"}, {"family": "Wullimann", "given": "David", "initials": "D", "orcid": "0000-0003-1632-0394", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4f555c04cc55493988f98507358b6d25.json"}}, {"family": "Cuapio", "given": "Angelica", "initials": "A"}, {"family": "Akber", "given": "Mira", "initials": "M"}, {"family": "Bogdanovic", "given": "Gordana", "initials": "G"}, {"family": "Muschiol", "given": "Sandra", "initials": "S"}, {"family": "\u00c5berg", "given": "Mikael", "initials": "M", "orcid": "0000-0002-7858-8233", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a08650cb00404b6dba35959f3cb0a53c.json"}}, {"family": "Lor\u00e9", "given": "Karin", "initials": "K", "orcid": "0000-0001-7679-9494", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1fe004217b9b4c5ab49fae1023ddedf1.json"}}, {"family": "Chen", "given": "Margaret S\u00e4llberg", "initials": "MS"}, {"family": "Ljungman", "given": "Per", "initials": "P", "orcid": "0000-0002-8281-3245", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/dca9a19fd8ec477baf2109f191599c6b.json"}}, {"family": "Buggert", "given": "Marcus", "initials": "M", "orcid": "0000-0003-0633-1719", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cf1bb88eef764f8bb81bdd6d8a231113.json"}}, {"family": "Aleman", "given": "Soo", "initials": "S"}, {"family": "Ljunggren", "given": "Hans-Gustaf", "initials": "HG", "orcid": "0000-0003-0908-7387", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0a134515bf6242818aad27e86a8da06a.json"}}], "type": "clinical trial", "published": "2024-11-00", "journal": {"title": "EBioMedicine", "issn": "2352-3964", "volume": "109", "pages": "105385", "issn-l": "2352-3964"}, "abstract": "Immunocompromised patients with primary and secondary immunodeficiencies have shown impaired responses to SARS-CoV-2 mRNA vaccines, necessitating recommendations for additional booster doses. However, longitudinal data reflecting the real-world impact of such recommendations remains limited.\n\nThis study represents a two-year follow-up of the COVAXID clinical trial, where 364 of the original 539 subjects consented to participate. 355 individuals provided blood samples for evaluation of binding antibody (Ab) titers and pseudo-neutralisation capacity against both the ancestral SARS-CoV-2 strain and prevalent Omicron variants. T cell responses were assessed in a subset of these individuals. A multivariate analysis determined the correlation between Ab responses and the number of vaccine doses received, documented infection events, immunoglobulin replacement therapy (IGRT), and specific immunosuppressive drugs. The original COVAXID clinical trial was registered in EudraCT (2021-000175-37) and clinicaltrials.gov (NCT04780659).\n\nSeveral of the patient groups that responded poorly to the initial primary vaccine schedule and early booster doses presented with stronger immunogenicity-related responses including binding Ab titres and pseudo-neutralisation at the 18- and 24-month sampling time point. Responses correlated positively with the number of vaccine doses and infection. The vaccine response was blunted by an immunosuppressive state due to the underlying specific disease and/or to specific immunosuppressive treatment.\n\nThe study results highlight the importance of continuous SARS-CoV-2 vaccine booster doses in building up and sustaining Ab responses in specific immunocompromised patient populations.\n\nThe present studies were supported by the European Research Council, Karolinska Institutet, Knut and Alice Wallenberg Foundation, Nordstjernan AB, Region Stockholm, and the Swedish Research Council.", "doi": "10.1016/j.ebiom.2024.105385", "pmid": "39395230", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11663764"}, {"db": "pii", "key": "S2352-3964(24)00421-3"}, {"db": "ClinicalTrials.gov", "key": "NCT04780659"}], "notes": [], "created": "2026-09-23T09:10:29.986Z", "modified": "2026-09-24T07:25:02.121Z"}, {"entity": "publication", "iuid": "7f676fd1be9f42038b0f4639f4f3cba5", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7f676fd1be9f42038b0f4639f4f3cba5.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7f676fd1be9f42038b0f4639f4f3cba5"}}, "title": "Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.", "authors": [{"family": "Blixt", "given": "Lisa", "initials": "L"}, {"family": "Bogdanovic", "given": "Gordana", "initials": "G"}, {"family": "Buggert", "given": "Marcus", "initials": "M"}, {"family": "Gao", "given": "Yu", "initials": "Y"}, {"family": "Hober", "given": "Sophia", "initials": "S"}, {"family": "Healy", "given": "Katie", "initials": "K"}, {"family": "Johansson", "given": "Hemming", "initials": "H"}, {"family": "Kjellander", "given": "Christian", "initials": "C"}, {"family": "Mravinacova", "given": "Sara", "initials": "S", "orcid": "0000-0003-1848-910X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c1e48837666642b18a977bb8a8c39603.json"}}, {"family": "Muschiol", "given": "Sandra", "initials": "S"}, {"family": "Nilsson", "given": "Peter", "initials": "P", "orcid": "0000-0002-4657-8532", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3db33fa3edb94febb8be7927a16838d0.json"}}, {"family": "Palma", "given": "Marzia", "initials": "M", "orcid": "0000-0003-4287-3179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fc1dd22fd3ca4eb3823866960fd240d2.json"}}, {"family": "Pin", "given": "Elisa", "initials": "E"}, {"family": "Smith", "given": "C I Edvard", "initials": "CIE", "orcid": "0000-0003-1907-3392", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/357ca5f9684948fb89f138da8c2c9aa2.json"}}, {"family": "Stromberg", "given": "Olga", "initials": "O"}, {"family": "S\u00e4llberg Chen", "given": "Margaret", "initials": "M", "orcid": "0000-0002-3793-4064", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/76491dcd7c2e462dbd3a21a98fe04e16.json"}}, {"family": "Zain", "given": "Rula", "initials": "R", "orcid": "0000-0001-8327-846X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/269ea37f5bd841c2921dc4a5eddc7e41.json"}}, {"family": "Hansson", "given": "Lotta", "initials": "L", "orcid": "0000-0001-6614-5737", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ad4bcbe463b0417e92258dbf5cb14886.json"}}, {"family": "\u00d6sterborg", "given": "Anders", "initials": "A", "orcid": "0000-0001-6489-4865", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/20620d6f76924b4a82239eb57061bd67.json"}}], "type": "journal article", "published": "2022-02-00", "journal": {"title": "Leukemia", "issn": "1476-5551", "volume": "36", "issue": "2", "pages": "476-481", "issn-l": "0887-6924"}, "abstract": "We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from a well-defined area during month 1-13 of the pandemic. Sixty patients (median age 71 y, range 43-97) were identified. Median CIRS was eight (4-20). Patients had indolent CLL (n = 38), had completed (n = 12) or ongoing therapy (n = 10). Forty-six patients (77%) were hospitalized due to severe Covid-19 and 11 were admitted to ICU. Severe Covid-19 was equally distributed across subgroups irrespective of age, gender, BMI, CLL status except CIRS (p < 0.05). Fourteen patients (23%) died; age \u226575 y was the only significant risk factor (p < 0.05, multivariate analysis with limited power). Comparing month 1-6 vs 7-13 of the pandemic, deaths were numerically reduced from 32% to 18%, ICU admission from 37% to 15% whereas hospitalizations remained frequent (86% vs 71%). Seroconversion occurred in 33/40 patients (82%) and anti-SARS-CoV-2 antibodies were detectable at six and 12 months in 17/22 and 8/11 patients, respectively. Most (13/17) had neutralizing antibodies and 19/28 had antibodies in saliva. SARS-CoV-2-specific T-cells (ELISpot) were detected in 14/17 patients. Covid-19 continued to result in high admission even among consecutive and young early- stage CLL patients. A robust and durable B and/or T cell immunity was observed in most convalescents.", "doi": "10.1038/s41375-021-01424-w", "pmid": "34564699", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8475381"}, {"db": "pii", "key": "10.1038/s41375-021-01424-w"}], "notes": [], "created": "2026-09-23T09:34:15.148Z", "modified": "2026-09-23T09:34:15.318Z"}]}